Mariko Ogura

List of Publications by Year
in descending order

62	530	933447 10	752698 20
papers	citations	h-index	g-index

69	69	69	844
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study. Journal of Gastrointestinal Cancer, 2023, 54, 475-484.	1.3	3
2	KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1273-1283.	2.5	6
3	Longâ€term outcomes of esophageal squamous cell carcinoma with invasion depth of pathological T1aâ€muscularis mucosae and T1bâ€submucosa by endoscopic resection followed by appropriate additional treatment. Digestive Endoscopy, 2022, 34, 793-804.	2.3	12
4	Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018. Oncologist, 2022, 27, e506-e517.	3.7	6
5	Safety and early efficacy results of a phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study).. Journal of Clinical Oncology, 2022, 40, 276-276.	1.6	5
6	Clinical usefulness of postoperative serum carcinoembryonic antigen in colorectal cancer patients with liver metastases.. Journal of Clinical Oncology, 2022, 40, 178-178.	1.6	0
7	Safety and Efficacy of Self-Expandable Metallic Stent Placement Using Low Radial Force Stent for Malignant Dysphagia after Radiotherapy. Digestion, 2022, 103, 261-268.	2.3	3
8	Treatment Strategy for Esophageal Squamous Cell Carcinoma With Endoscopic Intramural Metastasis. Cureus, 2022, 14, e23028.	0.5	1
9	Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer. International Journal of Colorectal Disease, 2022, 37, 1439-1447.	2.2	3
10	Safety evaluation of fixedâ€dose nivolumab in patients with gastric cancer. Health Science Reports, 2022, 5, .	1.5	4
11	Clinical impact of DNA methylation status on first-line antiepidermal growth factor receptor treatment in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, 3528-3528.	1.6	0
12	Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research. International Journal of Clinical Oncology, 2021, 26, 335-344.	2.2	6
13	Esophageal cancer patients' survival after complete response to definitive chemoradiotherapy: a retrospective analysis. Esophagus, 2021, 18, 629-637.	1.9	4
14	Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers. Cancer Chemotherapy and Pharmacology, 2021, 87, 767-777.	2.3	8
15	Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. Anticancer Research, 2021, 41, 3905-3915.	1.1	4
16	Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab. Oncology Letters, 2021, 22, 783.	1.8	7
17	Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as secondâ€line chemotherapy. Cancer Medicine, 2021, 10, 615-625.	2.8	10
18	Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer. Cancer Medicine, 2021, 10, 8820-8828.	2.8	10

#	Article	IF	Citations
19	A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study. Investigational New Drugs, 2020, 38, 111-119.	2.6	6
20	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. Cancer Chemotherapy and Pharmacology, 2020, 85, 265-272.	2.3	47
21	Neoadjuvant Chemoradiotherapy with Cisplatin Plus Fluorouracil for Borderline Resectable Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2020, 27, 1510-1517.	1.5	15
22	Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting. ESMO Open, 2020, 5, e000595.	4.5	2
23	Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. BMC Cancer, 2020, 20, 358.	2.6	4
24	A phase Ib study of nivolumab plus trastuzumab with S-1/capecitabine plus oxaliplatin for HER2-positive advanced gastric cancer (Ni-HIGH study): Safety evaluation.. Journal of Clinical Oncology, 2020, 38, 4525-4525.	1.6	3
25	Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study . Cancer Management and Research, 2019, Volume 11, 5757-5764.	1.9	4
26	Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 307-313.	2.3	9
27	Nonâ€V600E BRAF mutations and EGFR signaling pathway in colorectal cancer. International Journal of Cancer, 2019, 145, 2488-2495.	5.1	17
28	Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. Gastric Cancer, 2019, 22, 518-525.	5.3	44
29	Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. Journal of Gastroenterology, 2018, 53, 1186-1195.	5.1	67
30	Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer. Gastric Cancer, 2018, 21, 267-275.	5.3	12
31	A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. International Journal of Clinical Oncology, 2018, 23, 92-97.	2.2	13
32	Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer. Cancer Management and Research, 2018, Volume 10, 5283-5290.	1.9	5
33	Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake. OncoTargets and Therapy, 2018, Volume 11, 8301-8307.	2.0	10
34	Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab. Case Reports in Oncology, 2018, 11, 601-608.	0.7	4
35	Phase II trial of biweekly cetuximab and irinotecan as thirdâ€line therapy for pretreated KRAS exon 2 wildâ€type colorectal cancer. Cancer Science, 2018, 109, 2567-2575.	3.9	7
36	Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients. Targeted Oncology, 2017, 12, 341-351.	3.6	32

#	Article	IF	Citations
37	Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis. International Journal of Clinical Oncology, 2017, 22, 1060-1068.	2.2	9
38	Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients. BMC Cancer, 2017, 17, 38.	2.6	21
39	Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines.. Journal of Clinical Oncology, 2017, 35, 741-741.	1.6	4
40	Prognostic factors of trastuzumab-based chemotherapy in patients with advanced HER2 positive gastric cancer.. Journal of Clinical Oncology, 2017, 35, 41-41.	1.6	1
41	Analysis of predictive factors of ramucirumab plus paclitaxel for advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 185-185.	1.6	0
42	Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer. PLoS ONE, 2017, 12, e0176745.	2.5	3
43	Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy. Genes and Cancer, 2016, 7, 27-35.	1.9	15
44	Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer. Gastric Cancer, 2016, 19, 625-630.	5.3	4
45	Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and Clinical Oncology, 2015, 3, 1053-1057.	1.0	15
46	Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?. BMC Cancer, 2015, 15, 760.	2.6	4
47	Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Design, Development and Therapy, 2015, 9, 3099.	4.3	45
48	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Design, Development and Therapy, 2015, 9, 1653.	4.3	7
49	Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. OncoTargets and Therapy, 2015, 8, 243.	2.0	1
50	ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin.. Journal of Clinical Oncology, 2015, 33, 174-174.	1.6	0
51	A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).. Journal of Clinical Oncology, 2015, 33, 758-758.	1.6	0
52	Phenotypic differences among RAS mutational variations in colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2015, 33, 649-649.	1.6	0
53	Clinical features and outcome of advanced or metastatic gastric cancer in young adult,analysis of 97 cacses.. Journal of Clinical Oncology, 2015, 33, e15022-e15022.	1.6	0
54	Outcome of marked tumor marker increase in patients with advanced gastric cancer during chemotherapy without progression.. Journal of Clinical Oncology, 2015, 33, e15034-e15034.	1.6	0

#	Article	IF	Citations
55	Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): Analysis of 1,001 patients in single institute.. Journal of Clinical Oncology, 2014, 32, 3597-3597.	1.6	4
56	The efficacy of oxaliplatin-based adjuvant chemotherapy for stage IV colorectal cancer after R0 resection.. Journal of Clinical Oncology, 2014, 32, 638-638.	1.6	0
57	Efficacy of cetuximab-containing chemotherapy with or without bevacizumab in prior chemotherapies.. Journal of Clinical Oncology, 2014, 32, e14591-e14591.	1.6	0
58	Analysis of potential circulating angiogenic biomarkers for bevacizumab in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, e14601-e14601.	1.6	0
59	Survival analysis of linitis plastica advanced gastric cancer patients receiving S-1 plus cisplatin.. Journal of Clinical Oncology, 2013, 31, e15105-e15105.	1.6	0
60	Concordance of HER2 and its related molecules between primary and paired liver metastatic sites in gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4108-4108.	1.6	2
61	Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 610-610.	1.6	2
62	What are the limiting factorsÂrelated to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer?. Journal of Clinical Oncology, 2012, 30, 149-149.	1.6	0